Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
NCT06756321Phase 1Recruiting
- Sponsor
- Affiliated Hospital of Nantong University
- Start
- Sep 2023
- Primary completion
- Mar 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Anti-CD19 CAR T-cells (Beijing Doing Biomedical) and Anti-CD20/CD30-CAR-T cells in B cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL) and 1 more, sponsored by Affiliated Hospital of Nantong University. Primary endpoints: Evaluate safety and tolerability of CAR T-cells at 28 days and Evaluate the feasibility of administration of CAR T-cells at 12 months. Started Sep 2023; status: recruiting.
02
Drugs
Anti-CD19 CAR T-cells (Beijing Doing Biomedical)Anti-CD20/CD30-CAR-T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)T-cell lymphoma
Beyond the preview
Go deeper on NCT06756321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06756321.